Paranoid Schizophrenia, Combined with Cannabinoids Use: Epidemiological, Etiopathogenetic and Clinical Aspects (Literature Review)
Abstract
In recent studies interest of domestic and foreign researchers growth to comorbid pathology − a combination of psychiatric illness with substance use. The aim of the review was to examine the impact of the cannabinoids use in schizophrenic process and determine which aspects of paranoid schizophrenia, combined with the use of cannabinoids investigated insufficiently, is not covered in full, based on an analysis of the literature. Analysis of the literature suggests that the problem of combination of paranoid schizophrenia and cannabinoids use (both dependence on these substances and without it) is far from being resolved.
Downloads
References
Harchenko Je. M. [ta in.] Komorbidnist’ endogennyh psyhichnyh rozladiv iz zalezhnistju vid psyhoaktyvnyh rechovyn (stan problemy) [Komorbidnist endogenous mental disorders with substance dependence (state problem)]. Arhiv psyhiatrii’, 2009, no. 3, pp. 53-55. (In Ukr.)
Afanas’eva A. V. Osobennosti upotreblenija psihoaktivnyh veshhestv bol’nymi shizofreniej i ego vlijanie na techenie shizofrenicheskogo processa (Obzor literatury) [Features substance use patients with schizophrenia and its impact on the course of schizophrenia (Review of literature)]. Ukrai’ns’kyj visnyk psyhonevrologii’, 2011, no. 3, pp. 82-85. (In Russ.)
Arseneault L. [et al.] Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. British medical journal, 2002, no. 325, pp. 1212-1213.
Di Forti M., Murray R. M. Cannabis consumption and risk of developing schizophrenia: myth or reality? Social psychiatry and psychiatric epidemiology, 2005, no. 14, pp. 184-187.
Compton M. T. [et al.] Association of pre-onset cannabis, alcohol, and tobacco use with the age at onset of prodrome and age at onset of psychosis in first-episode patients. American journal of psychiatry, 2009, no. 11, pp. 1251-1257.
Compton M. T., Ramsay C. E. The impact of pre-onset cannabis use on age at onset of prodromal and psychotic symptoms. Primary рsychiatry, 2009, no. 16, pp. 35-43.
Semple D. M. [et al.] Cannabis as a risk factor for psychosis: systematic review. Journal of psychopharmacology, 2005, no. 2, pp. 187-194.
Subbotin O. Debyut shizofrenii kak sledstvie potrebleniya kannabisa v podrostkovom vozraste [The debut of schizophrenia as a result of consumption of cannabis in teens]. Vestnik Ivanovskoy meditsinskoy akademii, 2007, no. 1-2, pp. 84-88. (In Russ.)
Ferdinand R. F. [et al.] Cannabis – psychosis pathway independent of other types of psychopathology. Schizophrenia research, 2005, no. 2-3, pp. 289-295.
Dudin I. I. Premorbidnye sotsial’no-biologiche skie i lichnostno-psikhologicheskie faktory, predisponiruyushchie formirovaniyu zavisimosti ot kannabinoidov u bol’nykh s sochetannymi psikhicheskimi rasstroystvami [Premorbid social and biological and personal-psycho-logical factors predisposing the formation depending on cannabinoids in patients with concomitant mental disorders]. Dal’nevostochnyy meditsinskiy zhurnal, 2008, no. 3, pp. 84-86. (In Russ.)
van Kharen N. E. [i dr.] Shizofreniya kak progres siruyushchee zabolevanie golovnogo mozga [Schi zophrenia as a progressive disease of the brain]. Sotsial’naya i klinicheskaya psikhiatriya, 2008, no. 2, pp. 26-35. (In Russ.)
Zammit S. [et al.] Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts 1969: historical cohort study. British medical journal, 2002, no. 35, pp. 1199-1201.
Psikhicheskie posledstviya upotrebleniya kannabionoidov [Mental consequences of the use of cannabinoids]. Voprosy narkologii, 2002, no. 5, pp. 71 -72. (In Russ.)
Bokhan N. A. [i dr.] Komorbidnye addiktivnye rasstroystva u bol’nykh shizofreniey [Comorbid addictive disorders in patients with schizophrenia]. Narkologiya, 2002, no. 6, pp. 24-30. (In Russ.)
Maddock C., Babbs М. Intervention for cannabis misuse. Advances in psychiatric treatment, 2006, no. 12, pp. 432-439.
Arseneault L. [et al.]Causal association between cannabis and psychosis: examination of the evidence. British medical journal, 2004, no. 184, pp. 110-117.
Bazarbaeva L. E. Faktory, vliyayushchie na kliniku shizofrenii, oslozhnennoy narkomaniey (po materialam sudebno-psikhiatricheskikh ekspertiz) [Factors affecting the clinic schizophrenia complicated by drug addiction (based on forensic psychiatric examinations)]. Sibirskiy vestnik psikhiatrii i narkologii, 2009, no. 2, pp. 124-125. (In Russ.)
Henquet C. [et al.] Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British medical journal, 2005, no. 330, pp. 11-16.
Reinarman C. [et al.] Endocannabinoids in schizophrenia – do they play role? European psychiatry, 2004, no. 19, p. 79.
Fergusson D. M. [et al.] Cannabis dependence and psychotic symptoms in young people. Psychological medicine, 2003, no. 33, pp. 15-21.
Primenenie psikhoaktivnykh veshchestv pri shizofrenii. Marikhuana pri shizofrenii [The use of psychoactive substances in schizophrenia. Marijuana in schizophrenia]. Meditsinskiy portal Meduinver. Available at: http://meduniver.com/Medical/Psixology/154.html (14.12.2013). (In Russ.)
Blednykh M. A. Upotreblenie psikhoaktivnykh sredstv i priverzhennost’ k terapii u patsientov s vpervye diagnostirovannoy paranoidnoy shizofreniey [The use of psychoactive drugs and adherence to therapy in patients with newly diagnosed paranoid schizophrenia]. Nevrologicheskiy vestnik, 2012, no. 2, pp. 92-94. (In Russ.)
Kumra S. Schizophrenia and cannabis use. Minnesota medicine, 2007, no. 1, pp. 36-38.
Green A. I. [et al.] First-episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia research, 2004, no. 2-3, pp. 125-135.
Hambrecht M., Hafner H. Substance abuse and the onset of schizophrenia. Biological Psychiatry, 1996, no. 40, pp. 1155-1163.
Linszen D. [et al.] Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of general psychiatry, 1994, no. 51, pp. 273- 279.
Veen N. D. [et al.] Cannabis use and age at onset of schizophrenia. American journal of psychiatry, 2004, no. 3, pp. 501-506.
Ahmed A. O. [et al.] Handbook of schizophrenia spectrum disorders. Volume III [ed. by M. S. Ritsner]. Springer, Science, 2011, 462 p.
Smit F. [et al.] Cannabis use and the risk of later schizophrenia: a review. Addiction, 2004, no. 4, pp. 425-430.
Hall W. [et al.] Cannabis use and psychotic disorders: an update. Drug and alcohol review, 2004, no. 4, pp. 433-443.
Dvorjak S. V. [et al.] Likuvannja opioi’dnoi’ zalezhnosti agonistamy opioi’div [Treatment of opioid dependence opioid agonists]. Kiev, 2012, 283 p. (In Ukr.)
Weiser M., Noy S. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues in Clinical Neuroscience, 2005, no. 1, pp. 81-85.
Henquet C. [et al.] The environment and schizophrenia: the role of cannabis use. Schizophrenia bulletin, 2005, no. 3, pp. 608-612.
Cannabis use and brain structural alterations in first episode schizophrenia – a region of interest, voxel based morphometric study / S. S. Bangalore [et al.] // Schizophrenia research, 2008, no. 99. – Р. 1-6.
Veling W. [et al.] Cannabis use and genetic predisposition for schizophrenia: A casecontrol study. Psychological medicine, 2008, no. 38, pp. 1251-1256.
Trailin A. V., Levada O. A. Genetika i epigenetika shizofrenii [Genetics and epigenetics of schizophrenia]. NeyroNews, 2012, no. 6, pp. 18-28. (In Russ.)
Arseneault L. [et al] Marijuana and madness [ed. by D. Castle, R. Murray]. Cambridge, University Press, 2004, 218 p.
Ashton H. [et al.]. Cannabis – suicide, schizophrenia and other ill-effects. Australia, Drug Free Australia Ltd, 2009, 47 p.
Vidal C. N. [et al.] Dynamically spreading frontal and cingulate deficits mapped in adolescents with schizophrenia. Archives of general psychiatry, 2006, no. 63, pp. 25-34.
Rais M. [et al.] Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. American journal of psychiatry, 2008, no. 165, pp. 490-496.
Sewell R. A. [et al.] Cannabinoids and psychosis. International review of psychiatry, 2009, no. 2, pp. 152-162.
Eggan S. M. [et al.] Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Archives of general psychiatry, 2008, no. 7, pp. 772-784.
Desfosses J. [et al.] Endocannabinoids and schizophrenia. Pharmaceuticals, 2010, no. 3, pp. 3101-3126.
Wong D. F. [et al.] Quantification of cerebral cannabinoid receptors subtype 1 (cb1) in healthy subjects and schizophrenia by the novel pet radioligand [(11)c]omar. Neuroimage, 2010, no. 52, pp. 1505-1513.
Jenko K. J. [et al.] Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia. Schizophrenia research, 2012, no. 2-3, pp. 185-188.
Defekt mozga, svyazannyy s upotrebleniem kannabisa u patsientov s shizofreniey [The defect of the brain associated with cannabis use in patients with schizophrenia]. Narkologiya, 2007, no. 4, p. 74. (In Russ.)
Szeszko P. R. [et al.] Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. British Journal of Psychiatry, 2007, no. 190, pp. 230-236.
Rukovodstvo po narkologii. V 2 t. T. 1. [pod red. I. I. Ivantsa] [Guide to Addiction. In 2 t. T. 1. [ed. I. I. Ivanets]]. Moscow, Medpraktika Publ., 2002, 444 p. (In Russ.)
Simon A. E. [et al.]The Bruderholz Study: A prospective pilot study of patients at-risk for schizophrenia in North Western Switzerland. European psychiatry, 2004, no. 19, pp. 8-9.
Giuffrida A. [et al.] Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology, 2004, no. 29, pp. 2108-2114.
Marchi N. D. [et al.] Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids in health and disease, 2003, no. 2, pp. 5.
Roser P. [et al.] Potential antipsychotic properties of central cannabinoid (cb1) receptor antagonists. World journal of biological psychiatry, 2010, no. 11, pp. 208-219.
Desfosses J. [et al.] Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the «Mirror effect» of schizophrenia. Frontiers in psychiatry, 2012, no. 3, pp. 85.
Pogosov A. Gashishnaya narkomaniya [Cannabism]. Russkiy narodnyy server protiv narkotikov Available at: http://www.narcom.ru/publ/info/259 (28.10.2013). (In Russ.)
Lazur’evskiy G. V., Nikolaeva L. A. Kannabinoidy (narkoticheskie veshchestva konopli) [Cannabinoids (cannabis drugs)]. Chisinau, Shtiintsa Publ., 1972, 69 p. (In Russ.)
Tiwari A. K. [et al.] A common polymorphism in the cannabinoid receptor 1 (cnr1) gene is associated with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology, 2010, no. 35, pp. 1315-1324.
Ho B. C. [et al.] Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophrenia research, 2011, no. 1-3, pp. 66-75.
Tong D. [et al.] Association of single-nucleotide polymorphisms in the Cannabinoid Receptor 2 gene with schizophrenia in the Han Chinese population. Journal of molecular neuroscience, 2013, no. 2, pp. 454-460.
D`Souza D. C. [et al.]Delta-9-terahydrocannabinol effects in schizophrenia: implications for cognition, psychosis and addiction. Biological psychiatry, 2005, no. 57, pp. 594-608.
Schneider M., Koch M. Chronic pubertal, but not adult chtonic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology, 2003, no. 28, pp. 1760-1769.
Smesny S. [et al.] Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia. Neuropsychpharmacology, 2007, no. 32, pp. 2067-2073.
Ujike H., Morita Y. New perspectives in the studies on endocanabinoid and cannabis: cannabinoid receptors and schizophrenia. J. pharmacol sci., 2004, no. 96, pp. 376-81.
Bailey E. L., Swallow B. L. The relationship between cannabis use and schizotypal symptoms. European Psychiatry, 2004, no. 19, pp. 113-114.
Schiffman J [et al.] Symptoms of schizotypy precede cannabis use. Psychiatry Research, 2005, no. 134, pp. 37-42.
Miettunen J. [et al.] Association of cannabis use with prodromal symptoms of psychosis in adolescence. British Journal of Psychiatry, 2008, no. 192, pp. 470-471.
Romanenko R. N. [i dr.] Dinamika rasprostranennosti addiktivnogo povedeniya kak strategii sovladaniya s distressom, obuslovlennym negativnoy simptomatikoy, v prodrome pervichnogo epizoda shizofrenii [The dynamics of the prevalence of addictive behavior as a strategy of coping with the distress caused by negative symptoms in schizophrenia prodrome primary episode]. Prikladnye informatsionnye aspekty meditsiny, 2008, no. 11, 162-166. (In Russ.)
Mauri M. [et al.] Substance abuse in first-episode schizophrenic patients: a retrospective study. Clinical practice and epidemiology in mental health, 2006, no. 2, pp. 1-8.
Megrabyan A. A. [et al.] Rol’ gashishnoy intoksikatsii v klinicheskoy kartine shizofrenii [Role of hashish intoxication in the clinical picture of schizophrenia]. Alkogolizm i nekotorye drugie intoksikatsionnye zabolevaniya nervnoy sistemy i psikhicheskoy sfery. Materialy plenuma Vsesoyuznogo meditsinskogo obshchestva nevropatologov i psikhiatrov, 1972, pp. 99-102. (In Russ.)
Petrov R. V., Borisova L. F. Psikhicheskie rasstroystva i zavisimost’ [Mental disorders and dependency]. Novosti nauki i tekhniki, 2006, no. 9, pp. 18-20. (In Russ.)
Solowij N. [et al.] Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? Journal of psychiatry & neuroscience, 2007, no. 1, pp. 32-50.
Pyatnitskaya I. N. Obshchaya i chastnaya narko-logiya: rukovodstvo dlya vrachey [General and private drug and alcohol abuse: a guide for doctors]. Moscow, Medicine Publ., 2008, 640 p. (In Russ.)
Lichko A. E., Bitenskiy V. S. Podrostkovaya narkologiya [Teenage Drug Addiction]. Leningrad, Medicine Publ., 1991, 304 p. (In Russ.)
Korkina M. V., Lakosina N. D., Lichko A. E., Sergeev I. I. Psikhiatriya: uchebnik dlya studentov [Psychiatry: a textbook for students]. Moscow, MEDpress- info Publ., 2006, 576 p. (In Russ.)
Klimenko T. V. [et al.] Klinicheskiy patomorfoz zavisimosti ot kannabinoidov u bol’nykh shizofreniey (po dannym otdalennogo katamneza) [Clinical pathomorphosis depending on cannabinoids in patients with schizophrenia (according to remote catamnesis)]. Narkologiya, 2008, no. 1, pp. 41-45. (In Russ.)
Krishtal’ E. V. [et al.] Shizofreniya, oslozhnennaya upotrebleniem psikhoaktivnykh veshchestv, v sudebno-psikhiatricheskoy praktike [Schizophrenia is complicated by the use of psychoactive substances in forensic psychiatric practice]. Arhiv psyhiatrii’, 2008, no. 4, p. 56. (In Russ.)
Macleod J. Cannabis use and psychosis: the origins and implications of an association. Advances in psychiatric treatment, 2007, no. 13, pp. 400-411.
Maki P. [et al.] Predictors of schizophrenia – a review. British medical bulletin, 2005, no. 73-74, pp. 1-15.
Copyright (c) 2016 П. В. Кидонь
This work is licensed under a Creative Commons Attribution 4.0 International License.
